Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 15, 2020

Primary Completion Date

November 13, 2024

Study Completion Date

November 13, 2024

Conditions
Cytomegalovirus Anterior Uveitis
Interventions
DRUG

Valganciclovir Hydrochloride

21 to 28 days of oral valganciclovir treatment

DRUG

Ganciclovir Sodium

21 to 28 days of topical ganciclovir solution treatment

DRUG

Placebo Oral Tablet

21 to 28 days of placebo pill treatment

DRUG

Topical placebo

21 to 28 days of topical placebo treatment

Trial Locations (4)

94158

Proctor Foundation, UCSF, San Francisco

Unknown

Chulalongkorn University, Bangkok

Chiang Mai University, Chiang Mai

Khon Kaen University, Khon Kaen

All Listed Sponsors
collaborator

Huang Pacific Foundation

UNKNOWN

collaborator

Khon Kaen University

OTHER

collaborator

King Chulalongkorn Memorial Hospital

OTHER

lead

University of California, San Francisco

OTHER

NCT03586284 - Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes | Biotech Hunter | Biotech Hunter